Overall Score

Bargaining Power Of Suppliers

Supplier power is moderate because the company relies on specialized inputs and R&D-heavy operations, but its small scale limits negotiating leverage.

A relatively healthy current ratio of 2.27 and cash ratio of 1.75 reduce near-term supplier pressure by supporting working capital needs.

Bargaining Power Of Buyers

Buyer power remains moderate to elevated because the company has limited pricing power, reflected in a price-to-sales ratio of 12.0 and weak profitability.

Negative gross margin of -3.19% and operating margin of -33.29% suggest customers can resist price increases or that the company lacks differentiation.

Threat Of New Entrants

Barriers to entry are moderate due to the need for clinical, regulatory, and R&D capabilities, but the company’s small scale does not create strong structural protection.

High R&D spending at 19.95% of revenue indicates meaningful development intensity, yet the lack of profitability suggests limited moat strength.

Threat Of Substitutes

Substitution risk is moderate because alternative therapies or competing solutions can pressure demand in a small-cap biotech setting.

Weak operating performance and negative returns on capital imply the company has not yet established strong product differentiation to reduce substitution risk.

Competitive Rivalry

Competitive rivalry is high because the company operates with very weak margins and returns, which typically signals intense industry competition.

The business remains loss-making with EBIT margin of -33.18% and ROIC of -1.72%, indicating limited competitive cushion versus peers.